BioCryst Pharmaceuticals (NASDAQ:BCRX) Cut to “In-Line” at Evercore ISI

Evercore ISI lowered shares of BioCryst Pharmaceuticals (NASDAQ:BCRX – Get Rating) from an outperform rating to an in-line rating in a research note issued to investors on Friday morning, Marketbeat Ratings reports. They currently have $14.00 price objective on the biotechnology company’s stock.

BCRX has been the subject of several other reports. Cantor Fitzgerald reissued an overweight rating on shares of BioCryst Pharmaceuticals in a research report on Monday, May 9th. StockNews.com cut BioCryst Pharmaceuticals from a hold rating to a sell rating in a research note on Thursday, May 12th. Barclays upped their price objective on shares of BioCryst Pharmaceuticals from $12.00 to $14.00 and gave the company an equal weight rating in a report on Friday. Royal Bank of Canada cut their price target on shares of BioCryst Pharmaceuticals from $16.00 to $14.00 and set a sector perform rating on the stock in a research note on Tuesday, April 12th. Finally, Piper Sandler reduced their target price on BioCryst Pharmaceuticals from $24.00 to $19.00 in a research note on Thursday, May 5th. Eight analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of Hold and a consensus target price of $17.78.

BioCryst Pharmaceuticals Stock Performance

Shares of BCRX stock opened at $14.05 on Friday. The stock has a 50 day moving average price of $10.79 and a 200 day moving average price of $12.78. BioCryst Pharmaceuticals has a 52-week low of $7.61 and a 52-week high of $19.99. The firm has a market capitalization of $2.61 billion, a P/E ratio of -12.22 and a beta of 2.20.

BioCryst Pharmaceuticals (NASDAQ:BCRX – Get Rating) last posted its quarterly earnings results on Thursday, August 4th. The biotechnology company reported ($0.32) EPS for the quarter, topping the consensus estimate of ($0.36) by $0.04. During the same quarter in the previous year, the company posted ($0.24) earnings per share. As a group, sell-side analysts forecast that BioCryst Pharmaceuticals will post -1.34 EPS for the current year.

Institutional Trading of BioCryst Pharmaceuticals

Hedge funds have recently modified their holdings of the stock. Semmax Financial Advisors Inc. boosted its position in BioCryst Pharmaceuticals by 389.6% during the first quarter. Semmax Financial Advisors Inc. now owns 1,699 shares of the biotechnology company’s stock worth $28,000 after purchasing an additional 1,352 shares in the last quarter. Strs Ohio purchased a new position in BioCryst Pharmaceuticals during the first quarter worth approximately $32,000. Fairfield Bush & CO. purchased a new position in BioCryst Pharmaceuticals during the first quarter worth approximately $34,000. CWM LLC purchased a new position in BioCryst Pharmaceuticals during the fourth quarter worth approximately $47,000. Finally, Lazard Asset Management LLC purchased a new position in BioCryst Pharmaceuticals during the first quarter worth approximately $57,000. Hedge funds and other institutional investors own 63.86% of the company’s stock.

About BioCryst Pharmaceuticals

(Get Rating)

BioCryst Pharmaceuticals, Inc, a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.